Department of Thyroid and Neck Tumor, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, 300121, China.
Langenbecks Arch Surg. 2024 Aug 6;409(1):241. doi: 10.1007/s00423-024-03431-8.
Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are rare, aggressive thyroid cancers with poor prognosis. At present, there are a limited number of research reports on PDTC and ATC. The study aimed to analysis the predictive value of hematologic parameters and clinicopathological features of PDTC and ATC.
This study retrospectively analyzed 67 patients at Tianjin Medical University Cancer Hospital from 2007 to 2019. We analyzed the clinicopathological features and survival outcomes of PDTC and ATC.
This study showed that positive D-dimer, a high NLR, and a high PLR were more common in death patients. At the end of follow-up, 22 (32.8%) patients were alive at the time of study and 45 (67.2%) patients died from thyroid carcinoma. Disease-related death rates were 93.8% in ATC and 42.9% in the PDTC group. The median overall survival (OS) was 2.5 (0.3-84) months for patients with ATC, and 56 (3-113) months of PDTC patients. Univariate analysis showed that age at diagnosis and surgery were associations with OS in ATC patients, what's more, age at diagnosis, a high NLR, a high PLR, and positive D-dimer were associations with OS in PDTC patients. Multivariate analysis revealed that age at diagnosis was an independent association with OS in ATC patients.
The hematologic parameters and clinicopathological features may provide predictive value of prognosis for patients with PTDC and ATC.
低分化甲状腺癌（PDTC）和间变性甲状腺癌（ATC）是罕见的侵袭性甲状腺癌，预后不良。目前，关于 PDTC 和 ATC 的研究报告数量有限。本研究旨在分析 PDTC 和 ATC 的血液学参数和临床病理特征的预测价值。
本研究回顾性分析了 2007 年至 2019 年在天津医科大学肿瘤医院就诊的 67 例患者。分析 PDTC 和 ATC 的临床病理特征和生存结局。
本研究表明，死亡患者中 D-二聚体阳性、NLR 高和 PLR 高更为常见。在随访结束时，研究时 22（32.8%）例患者存活，45（67.2%）例患者死于甲状腺癌。ATC 组疾病相关死亡率为 93.8%，PDTC 组为 42.9%。ATC 患者的中位总生存期（OS）为 2.5（0.3-84）个月，PDTC 患者为 56（3-113）个月。单因素分析显示，诊断时年龄和手术与 ATC 患者的 OS 相关，此外，诊断时年龄、NLR 高、PLR 高和 D-二聚体阳性与 PDTC 患者的 OS 相关。多因素分析显示，诊断时年龄是 ATC 患者 OS 的独立相关因素。
血液学参数和临床病理特征可能为 PTDC 和 ATC 患者的预后提供预测价值。
